{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:20:44Z","timestamp":1769919644749,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.humpath.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:14:06Z","timestamp":1473380046000},"page":"123-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells"],"prefix":"10.1016","volume":"58","author":[{"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.08.005_bb0005","first-page":"519","article-title":"Ovarian cancer - diagnostic, biological and prognostic aspects","volume":"10","author":"Davidson","year":"2014","journal-title":"Womens Health"},{"key":"10.1016\/j.humpath.2016.08.005_bb0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/14737159.2016.1156532","article-title":"Recently identified drug resistance biomarkers in ovarian cancer","volume":"16","author":"Davidson","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.humpath.2016.08.005_bb0015","doi-asserted-by":"crossref","first-page":"708036","DOI":"10.1155\/2012\/708036","article-title":"Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity","volume":"2012","author":"Jaggupilli","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","article-title":"Ovarian cancer stem cell markers: prognostic and therapeutic implications","volume":"322","author":"Burgos-Ojeda","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2016.08.005_bb0025","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/REP-14-0234","article-title":"Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm","volume":"149","author":"Garson","year":"2015","journal-title":"Reproduction"},{"key":"10.1016\/j.humpath.2016.08.005_bb0030","series-title":"Serous effusions","year":"2011"},{"key":"10.1016\/j.humpath.2016.08.005_bb0035","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1158\/1078-0432.CCR-06-1059","article-title":"Gene expression signatures differentiate ovarian\/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.08.005_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2014.10.004","article-title":"The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage serous ovarian carcinoma effusions","volume":"46","author":"Davidson","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2012.05.014","article-title":"Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update","volume":"44","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/modpathol.2013.34","article-title":"Value of PAX8, PAX2, napsin a, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma","volume":"26","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2012.200","article-title":"Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas","volume":"26","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0060","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0b013e3181da7687","article-title":"PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma","volume":"34","author":"Laury","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0065","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/jclinpath-2015-203211","article-title":"Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses","volume":"69","author":"Kawai","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/PAI.0b013e3182366531","article-title":"Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of m\u00fcllerian origin?","volume":"20","author":"Gao","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0075","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cncy.21392","article-title":"Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology","volume":"122","author":"Jo","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0085","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1309\/V025QRN3R9CJGNPX","article-title":"The diagnostic role of claudins in serous effusions","volume":"127","author":"Kleinberg","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/dc.20771","article-title":"MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells","volume":"35","author":"Davidson","year":"2007","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.humpath.2015.08.020","article-title":"MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions","volume":"47","author":"Davidson","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0100","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/PAS.0b013e3181b6bde3","article-title":"Tenascin-X is a novel diagnostic marker of malignant mesothelioma","volume":"33","author":"Yuan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0105","first-page":"2745","article-title":"CD24, COX-2, and p 53 in epithelial ovarian cancer and its clinical significance","volume":"4","author":"Zhu","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"key":"10.1016\/j.humpath.2016.08.005_bb0110","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","article-title":"CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival","volume":"161","author":"Kristiansen","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2016.08.005_bb0115","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2016.08.005_bb0120","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10585-012-9482-4","article-title":"CD44+\/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival","volume":"29","author":"Meng","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.humpath.2016.08.005_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2007.08.064","article-title":"Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM","volume":"107","author":"Runz","year":"2007","journal-title":"Gynecol Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:44Z","timestamp":1601055944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716302039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":25,"alternative-id":["S0046817716302039"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.08.005","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}